Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.56 |
| ▸ | AGXT | P21549 | 2/20 | 0.56 |
| ▸ | MAOB | P27338 | 12/20 | 0.49 |
| ▸ | MAOA | P21397 | 4/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.39 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6525763 | 0.86 | IDO1 (0.49) | IDO1AGXTMAOBMAOATAAR1 | |
| SCHEMBL9197307 | 0.84 | IDO1 (0.50) | IDO1AGXTMAOBMAOATAAR1 | |
| SCHEMBL333905 | 0.84 | TAAR1 (0.46) | IDO1AGXTMAOBTAAR1 | |
| SCHEMBL4976106 | 0.83 | IDO1 (0.36) | IDO1AGXT | |
| SCHEMBL31139306 | 0.83 | IDO1 (0.36) | IDO1AGXT | |
| SCHEMBL9849151 | 0.83 | GABRG2 (0.41) | IDO1AGXTMAOB | |
| SCHEMBL6490220 | 0.82 | IDO1 (0.48) | IDO1AGXT | |
| SCHEMBL1438559 | 0.82 | IDO1 (0.44) | IDO1AGXT | |
| SCHEMBL3825220 | 0.82 | CYP2A6 (0.37) | IDO1AGXTMAOBMAOA | |
| SCHEMBL3643273 | 0.81 | TAAR1 (0.44) | IDO1AGXTMAOBTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0874841-B1 | 1-BENZENESULFONYL PYRROLIDINE DERIVATIVES AS BRADYKININ RECEPTOR ANTAGONISTS | FOURNIER IND & SANTE (FR) | 2001-10-04 | — | — | EP | claimed |
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | SERVIER LAB (FR) | 2026-01-01 | — | — | US | disclosed |
| US-20250354195-A1 | METHOD OF SCREENING | UNIV DUNDEE (GB) | 2025-11-20 | — | — | US | disclosed |
| US-20250320204-A1 | 7-AZA BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | RIBOSCIENCE LLC (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4551566-A1 | NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | Les Laboratoires Servier (FR) | 2025-05-14 | — | — | EP | disclosed |
| US-20240132507-A1 | TDO2 and IDO1 Inhibitors | GENENTECH, INC. | 2024-04-25 | — | — | US | disclosed |
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-15 | — | — | US | disclosed |
| WO-2024008941-A1 | NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2024-01-11 | — | — | WO | disclosed |
| US-11827639-B2 | TDO2 and IDO1 inhibitors | GENENTECH, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827639-B2 | TDO2 and IDO1 inhibitors | GENENTECH, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| WO-1999065893-A1 | NOVEL BENZOPYRAN OR THIOBENZOPYRAN DERIVATIVES | C & C RESEARCH LABORATORIES (KR) | 1999-12-23 | — | — | WO | disclosed |
| EP-0710646-B1 | 1,5-Disubstituted 7a-methylperhydroinden-3a-ol derivatives, active on the cardiovascular system, processes for their preparation and pharmaceutical compositions containing them | SIGMA TAU IND FARMACEUTI (IT) | 1998-12-16 | — | — | EP | disclosed |
| US-5707987-A | BACTERICIDE ANTIBIOTICS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1998-01-13 | — | — | US | disclosed |
| US-5705531-A | CONGESTIVE HEART FAILURE AND HYPERTENSION TREATMENT | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1998-01-06 | — | — | US | disclosed |
| EP-0747381-A1 | CARBAPENEM DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1996-12-11 | — | — | EP | disclosed |
| EP-0710646-A1 | 1,5-disubstituted 7a-methylperhydroinden-3a-ol derivatives, active on the cardiovascular system, processes for their preparation and pharmaceutical compositions containing them | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1996-05-08 | — | — | EP | disclosed |
| US-5446055-A | Antiallergens, antiinflammatory agents | ABBOTT LABORATORIES (US) | 1995-08-29 | — | — | US | disclosed |
| EP-0184384-B1 | SUBSTITUTED DIHYDROQUINOLONE CARBOXYLIC ACIDS, ANTI-BACTERIAL COMPOSITIONS CONTAINING THEM | PFIZER INC. (US) | 1989-08-02 | — | — | EP | disclosed |
| US-4623650-A | BACTERICIDES | PFIZER INC. (US) | 1986-11-18 | — | — | US | disclosed |
| EP-0184384-A1 | Substituted dihydroquinolone carboxylic acids, anti-bacterial compositions containing them | PFIZER INC. (US) | 1986-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132507-A1 | TDO2 and IDO1 Inhibitors | IDO1, TDO2, IDO2 | IDO1 1/4885AGXT 357/4885MAOB 40/4885 |
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | BCL2, BCL2A1, BAX | IDO1 4559/4885AGXT 3852/4885MAOB 3576/4885 |
| US-11827639-B2 | TDO2 and IDO1 inhibitors | IDO1, TDO2, IDO2 | IDO1 1/4885AGXT 357/4885MAOB 40/4885 |
| US-20250320204-A1 | 7-AZA BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | ENPP1, ENPP3, PDE7A | IDO1 633/4885AGXT 2986/4885MAOB 374/4885 |
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | GSPT1, GGT1, VHL | IDO1 1102/4885AGXT 349/4885MAOB 1155/4885 |
| US-20250354195-A1 | METHOD OF SCREENING | PAICS, COASY, ABCG2 | IDO1 3398/4885AGXT 1326/4885MAOB 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.